255 lines
10 KiB
JSON
255 lines
10 KiB
JSON
{
|
|
"trade_date": "2026-04-15",
|
|
"tickers": [
|
|
"RVMD",
|
|
"CAR",
|
|
"ORCL",
|
|
"HOLX",
|
|
"EXAS",
|
|
"CINF",
|
|
"CTRA",
|
|
"CMS",
|
|
"NI",
|
|
"DTE",
|
|
"NDAQ",
|
|
"GTLS",
|
|
"COP",
|
|
"SMC",
|
|
"LW",
|
|
"SG",
|
|
"HTO",
|
|
"RPAY",
|
|
"BETR",
|
|
"GF",
|
|
"MNR",
|
|
"ACET",
|
|
"CHPT",
|
|
"WKSP",
|
|
"CNXC",
|
|
"SVBL",
|
|
"FROPX",
|
|
"FRBBX",
|
|
"SWZ",
|
|
"COHR",
|
|
"TMUS",
|
|
"T",
|
|
"VZ",
|
|
"VLN",
|
|
"GLOO",
|
|
"WDAY",
|
|
"ABX",
|
|
"ACHC",
|
|
"AI",
|
|
"ARCT",
|
|
"ANAB",
|
|
"MTB",
|
|
"HOMB",
|
|
"JBHT",
|
|
"MIND",
|
|
"PNC",
|
|
"GSBC",
|
|
"MS",
|
|
"NYC",
|
|
"BAC",
|
|
"SLG",
|
|
"ANGO",
|
|
"GIPR",
|
|
"SLP",
|
|
"KRUS",
|
|
"KMX",
|
|
"PXED",
|
|
"RPM",
|
|
"NEOG",
|
|
"RELL",
|
|
"LEXX",
|
|
"MOS",
|
|
"QSI",
|
|
"SRPT",
|
|
"QQQ",
|
|
"IV"
|
|
],
|
|
"filtered_tickers": [
|
|
"ABX",
|
|
"ACHC",
|
|
"AI",
|
|
"ARCT",
|
|
"ANAB",
|
|
"ANGO",
|
|
"GIPR",
|
|
"SLP",
|
|
"KRUS",
|
|
"KMX",
|
|
"PXED",
|
|
"RPM",
|
|
"NEOG",
|
|
"RELL",
|
|
"LEXX",
|
|
"CAR",
|
|
"ORCL",
|
|
"CINF",
|
|
"CTRA",
|
|
"NI",
|
|
"DTE",
|
|
"COP",
|
|
"SMC",
|
|
"SG",
|
|
"HTO",
|
|
"RPAY",
|
|
"GF",
|
|
"MNR",
|
|
"ACET",
|
|
"WKSP",
|
|
"CNXC",
|
|
"SVBL",
|
|
"FROPX",
|
|
"FRBBX",
|
|
"SWZ",
|
|
"MTB",
|
|
"HOMB",
|
|
"JBHT",
|
|
"MIND",
|
|
"PNC",
|
|
"GSBC",
|
|
"MS",
|
|
"NYC",
|
|
"BAC",
|
|
"SLG",
|
|
"CMS",
|
|
"NDAQ",
|
|
"GTLS",
|
|
"COHR",
|
|
"TMUS",
|
|
"T",
|
|
"VZ",
|
|
"VLN",
|
|
"GLOO",
|
|
"WDAY",
|
|
"MOS",
|
|
"QSI",
|
|
"SRPT",
|
|
"QQQ"
|
|
],
|
|
"final_ranking": [
|
|
{
|
|
"rank": 1,
|
|
"ticker": "ANAB",
|
|
"company_name": "AnaptysBio",
|
|
"current_price": 70.22,
|
|
"strategy_match": "short_squeeze",
|
|
"final_score": 95,
|
|
"confidence": 9,
|
|
"risk_level": "high",
|
|
"reason": "ANAB perfectly aligns a hard fundamental catalyst with an extreme short squeeze setup. The company's spin-off into First Tracks Biotherapeutics is effective April 20 (in 5 days), providing an urgent mechanism to force covering of the 30.6% short interest (9.8 days to cover). Technicals heavily support the upside, featuring a MACD bullish crossover, rising OBV (16.3M), and the price holding a strong 19.8% above its 50 SMA. The primary risk is high volatility (ATR of $4.18) and the potential for a 'sell the news' reaction post-spin-off.",
|
|
"description": "Clinical-stage biopharmaceutical company focused on immunology and inflammation therapeutics."
|
|
},
|
|
{
|
|
"rank": 2,
|
|
"ticker": "ORCL",
|
|
"company_name": "Oracle Corporation",
|
|
"current_price": 163.0,
|
|
"strategy_match": "technical_breakout",
|
|
"final_score": 88,
|
|
"confidence": 8,
|
|
"risk_level": "moderate",
|
|
"reason": "ORCL recently broke out, closing 2.9% above its 20-day high on 2.5x average volume following news of an AI utility platform and a Bloom Energy partnership. The technical posture is highly robust, trading 8.8% above its 50 SMA with a fresh MACD bullish crossover and rising on-balance volume. The fundamental catalyst of AI monetization combined with heavy volume confirmation signals strong institutional sponsorship. The main risk is short-term mean reversion as it currently trades near the upper Bollinger Band (109% position).",
|
|
"description": "Multinational computer technology corporation known for its enterprise software, cloud computing, and database products."
|
|
},
|
|
{
|
|
"rank": 3,
|
|
"ticker": "RPAY",
|
|
"company_name": "Repay Holdings",
|
|
"current_price": 3.07,
|
|
"strategy_match": "insider_buying",
|
|
"final_score": 82,
|
|
"confidence": 8,
|
|
"risk_level": "moderate",
|
|
"reason": "RPAY presents a compelling alignment of insider buying and activist pressure, with 10% owner Forager Fund recently purchasing $2.4M in stock. This coincides with the company adopting a poison pill to defend against activist accumulation, creating a strong fundamental floor and catalyst for value realization. Technicals show a supportive base with a MACD bullish crossover, rising OBV, and price trading 3.6% above the 50 SMA. Given its low share price, volatility is inherent, but the activist narrative heavily skews the risk/reward to the upside.",
|
|
"description": "Provider of integrated payment processing solutions to industry-specific markets."
|
|
},
|
|
{
|
|
"rank": 4,
|
|
"ticker": "ARCT",
|
|
"company_name": "Arcturus Therapeutics",
|
|
"current_price": 8.68,
|
|
"strategy_match": "short_squeeze",
|
|
"final_score": 78,
|
|
"confidence": 7,
|
|
"risk_level": "high",
|
|
"reason": "ARCT screens exceptionally well for a short squeeze, heavily burdened with 31.5% of its float sold short and a massive 12.7 days to cover. Technical confirmation is highly present as the stock remains in a confirmed uptrend, trading 15.5% above its 50 SMA with rising on-balance volume and a bullish RSI of 67.1. Because of the extended days-to-cover ratio, any positive PR could ignite a rapid covering cycle. Binary biotech risks and a high ATR (5.5% of price) warrant careful position sizing.",
|
|
"description": "Clinical-stage mRNA medicines and vaccines company."
|
|
},
|
|
{
|
|
"rank": 5,
|
|
"ticker": "SG",
|
|
"company_name": "Sweetgreen",
|
|
"current_price": 6.2,
|
|
"strategy_match": "insider_buying",
|
|
"final_score": 76,
|
|
"confidence": 7,
|
|
"risk_level": "high",
|
|
"reason": "SG saw heavy institutional conviction with Goldman Sachs acquiring $3.38M in stock, a massive signal for a company of this market cap. The technical setup strongly confirms this accumulation, featuring a MACD bullish crossover, rising OBV, and a strong uptrend (+11.1% above 50 SMA). The 8% intraday move indicates momentum is already aggressively accelerating. The primary risk is chasing the extended move near the upper Bollinger Band (97% position), which could lead to short-term pullbacks.",
|
|
"description": "Fast-casual restaurant chain specializing in custom salads and warm bowls."
|
|
},
|
|
{
|
|
"rank": 6,
|
|
"ticker": "RPM",
|
|
"company_name": "RPM International",
|
|
"current_price": 108.67,
|
|
"strategy_match": "pead_drift",
|
|
"final_score": 74,
|
|
"confidence": 7,
|
|
"risk_level": "low",
|
|
"reason": "RPM delivered a massive 59.9% earnings surprise 7 days ago, leaving the window wide open for post-earnings announcement drift (PEAD). While the price has remained relatively flat over the last 5 days (-0.05%), the OBV is showing a bullish divergence (rising to 1.7M), indicating quiet institutional accumulation. The stock remains in a steady uptrend above its 50 SMA with low volatility (3.3% ATR). A failure to break near-term Fibonacci resistance at $110.76 could stall momentum, but downside appears limited.",
|
|
"description": "Manufacturer of specialty coatings, sealants, building materials, and related services."
|
|
},
|
|
{
|
|
"rank": 7,
|
|
"ticker": "NI",
|
|
"company_name": "NiSource Inc.",
|
|
"current_price": 47.22,
|
|
"strategy_match": "volume_divergence",
|
|
"final_score": 72,
|
|
"confidence": 7,
|
|
"risk_level": "low",
|
|
"reason": "NI exhibits a classic multi-week accumulation setup, with OBV running +24.2% above average volume despite a relatively flat 20-day price trend. Technicals confirm the underlying institutional buying, showing a bullish OBV divergence (133.2M) and price holding 2.0% above the 50 SMA. This low-volatility (1.8% ATR) setup provides a safe, asymmetric entry for a defensive stock. The primary risk is macroeconomic sector rotation away from utilities if bond yields spike.",
|
|
"description": "Energy holding company providing natural gas and electricity."
|
|
},
|
|
{
|
|
"rank": 8,
|
|
"ticker": "SRPT",
|
|
"company_name": "Sarepta Therapeutics",
|
|
"current_price": 22.15,
|
|
"strategy_match": "social_dd",
|
|
"final_score": 70,
|
|
"confidence": 6,
|
|
"risk_level": "moderate",
|
|
"reason": "SRPT combines strong social sentiment with excellent technical confirmation, trading in a steady uptrend 17.2% above its 50 SMA. Momentum indicators are heavily supportive, with a bullish MACD, rising OBV (52.8M), and price holding comfortably above the 20 EMA. The 'social_dd' scanner's 55% historical 30-day win rate adds statistical edge to the setup. As with any biotech, unforeseen clinical or regulatory developments remain the primary downside risk.",
|
|
"description": "Commercial-stage biopharmaceutical company focused on precision genetic medicine."
|
|
},
|
|
{
|
|
"rank": 9,
|
|
"ticker": "RELL",
|
|
"company_name": "Richardson Electronics",
|
|
"current_price": 13.56,
|
|
"strategy_match": "pead_drift",
|
|
"final_score": 68,
|
|
"confidence": 6,
|
|
"risk_level": "high",
|
|
"reason": "RELL is in the midst of a strong PEAD move after beating earnings estimates by 52.5% 7 days ago. The stock is up 15.3% over the last 5 days, supported by rising OBV (4.0M) and a bullish MACD, and is trading firmly above its 50 SMA (+12.5%). While the momentum is powerful, the stock is trading near its upper Bollinger Band (92% position) with high volatility (6.5% ATR), which warrants caution against sudden mean-reversion pullbacks.",
|
|
"description": "Distributor of electronic components and enterprise computing solutions."
|
|
},
|
|
{
|
|
"rank": 10,
|
|
"ticker": "DTE",
|
|
"company_name": "DTE Energy",
|
|
"current_price": 147.74,
|
|
"strategy_match": "volume_divergence",
|
|
"final_score": 68,
|
|
"confidence": 6,
|
|
"risk_level": "low",
|
|
"reason": "DTE shares a highly similar setup to NI, showing a clear bullish OBV divergence (+23.9% of avg vol) against a flat 20-day price trend. The technical posture is resilient, with the stock in a strong uptrend and trading 2.4% above its 50 SMA. With earnings approaching in 8 days, this quiet accumulation suggests institutions are positioning for a strong print. The extremely low ATR (1.7%) makes this a defensive play, though the impending earnings date introduces binary event risk.",
|
|
"description": "Diversified energy company involved in the development and management of energy-related businesses."
|
|
}
|
|
],
|
|
"status": "ranked"
|
|
} |